Sandra Horning - Foundation Medicine Director
Director
Ms. Sandra Horning, M.D., has served as a member of our Board of Directors of the company . Dr. Horning has served as a member of our Board of Directors since April 2015. Dr. Horning currently serves as global head, product development and chief medical officer for Roche and Genentech. She joined Roche in late 2009 as global head of oncology product development. She is an emerita professor of .medicine at Stanford University where she served as a tenured professor, practicing oncologist and investigator for more than two decades since 2014.
| Age | 68 |
| Tenure | 10 years |
| Professional Marks | Ph.D |
| Phone | 617 418-2200 |
| Web | www.foundationmedicine.com |
Foundation Medicine Management Efficiency
Foundation Medicine's management efficiency ratios could be used to measure how well Foundation Medicine manages its routine affairs as well as how well it operates its assets and liabilities.The company has 90 M in debt with debt to equity (D/E) ratio of 476.2, demonstrating that the company may be unable to create cash to meet all of its financial commitments. Foundation Medicine has a current ratio of 2.22, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due. Debt can assist Foundation Medicine until it has trouble settling it off, either with new capital or with free cash flow. So, Foundation Medicine's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Foundation Medicine sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Foundation to invest in growth at high rates of return. When we think about Foundation Medicine's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Steven Gunby | Arrow Electronics | 63 | |
| Eric Olsen | Cimpress NV | 52 | |
| Mark Thomas | Cimpress NV | 63 | |
| Peter Gyenes | Cimpress NV | 69 | |
| Paolo Cesare | Cimpress NV | 57 | |
| Gail Hamilton | Arrow Electronics | 71 | |
| Barry Perry | Arrow Electronics | 74 | |
| Martha Keeth | Arrow Electronics | 73 | |
| Steven OBrien | Arrow Electronics | N/A | |
| William Austen | Arrow Electronics | 62 | |
| Fabian Garcia | Arrow Electronics | 61 | |
| Nadia Shouraboura | Cimpress NV | 47 | |
| Laurel Krzeminski | Arrow Electronics | 66 | |
| John Gavin | Cimpress NV | 62 | |
| Scott Vassalluzzo | Cimpress NV | 46 | |
| Zachary Sternberg | Cimpress NV | 32 | |
| Sophie Gasperment | Cimpress NV | 53 | |
| Andrew Kerin | Arrow Electronics | 57 | |
| Richard Hill | Arrow Electronics | 69 | |
| Stephen Patrick | Arrow Electronics | 71 | |
| Ben Allanson | Stagwell | N/A | |
Management Performance
| Return On Equity | -2.0E-4 | |||
| Return On Asset | -1.0E-4 |
Foundation Medicine Leadership Team
Elected by the shareholders, the Foundation Medicine's board of directors comprises two types of representatives: Foundation Medicine inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Foundation. The board's role is to monitor Foundation Medicine's management team and ensure that shareholders' interests are well served. Foundation Medicine's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Foundation Medicine's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Daniel Day, Director | ||
| Michael Varney, Director | ||
| Krishna Yeshwant, Independent Director | ||
| David Daly, Chief Commercial Officer | ||
| David Schenkein, Independent Director | ||
| Melanie Nallicheri, Chief business Officer and head of Biopharma | ||
| Alexis Borisy, Chairman of the Board, Co-Founder | ||
| Steven Kafka, Pres and COO | ||
| Evan Jones, Independent Director | ||
| Vincent Miller, Chief Medical Officer | ||
| Konstantin Fiedler, COO | ||
| Michael Pellini, President CEO, Director | ||
| Robert Hesslein, Senior Vice President General Counsel | ||
| Sandra Horning, Director | ||
| Michael Doherty, Head of Product Development | ||
| Jason Ryan, CFO | ||
| Michael Dougherty, Director | ||
| Tom Civik, Chief Commercial Officer | ||
| Troy Cox, CEO, Director | ||
| Thomas Civik, Chief Commercial Officer |
Foundation Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Foundation Medicine a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.0E-4 | |||
| Return On Asset | -1.0E-4 | |||
| Profit Margin | (0.0001) % | |||
| Operating Margin | (83.98) % | |||
| Current Valuation | 5.09 B | |||
| Shares Outstanding | 37.14 M | |||
| Shares Owned By Insiders | 58.74 % | |||
| Shares Owned By Institutions | 36.24 % | |||
| Number Of Shares Shorted | 2.35 M | |||
| Price To Earning | (9.70) X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Other Consideration for investing in Foundation Stock
If you are still planning to invest in Foundation Medicine check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Foundation Medicine's history and understand the potential risks before investing.
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing |